Orphan Therapeutics Accelerator (OTXL) in-licensed an investigational gene therapy program for ornithine transcarbamylase deficiency (OTCD), naming it OTXL-101. The program originated from collaborations between University College London and the Children’s Medical Research Institute and is based on an AAV-based approach previously known as AAVLK03hOTC. The nonprofit described OTXL-101 as its first in-licensed therapy, tying the move to a broader strategy aimed at restarting shelved cell and gene therapy programs using tax and incentive structures. OTXL also highlighted parallel initiatives including Orphan ClinDevNet and the CGTxchange marketplace. The transaction is an example of how incentive-driven nonprofit ecosystems are trying to translate preclinical rare-disease work into development programs when traditional backers deprioritize assets.